Smart contact lenses Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief
What This Brief Covers
This Meticulous Next™ brief examines smart contact lenses, lenses that carry sensors, drug reservoirs or displays and read or act on the eye and its fluids. It tests whether lenses move from one approved monitoring device and many prototypes to a regulated product category in eye care and a wearable platform by 2036, and what that means for eye care companies, medical device makers, technology groups and patients.
One monitoring lens is already on the market. The Sensimed Triggerfish is an FDA-approved lens for 24-hour monitoring of changes linked to intraocular pressure in glaucoma. The device reports ocular dimensional changes and not conventional pressure in millimetres of mercury. The conclusion is that regulators have accepted a smart lens for clinical use, although the output is a pattern and not a direct pressure reading, and this limits how far the product can replace standard tests.
Research is moving toward lenses that act as well as sense. On 8 April 2026 the Terasaki Institute in California reported in Science Translational Medicine a lens that tracks intraocular pressure with no electronics or battery and releases drug in pulses when pressure rises, tested in live rabbits and in cow eyes. The developers plan a small human trial, and the monitoring part could reach approval faster than the drug-delivery part. The conclusion is that closed-loop treatment lenses are preclinical, and monitoring comes to patients first.
Display lenses attract the largest funding. XPANCEO, a company in the United Arab Emirates, raised USD 250 million in July 2025 at a valuation of USD 1.35 billion, led by Opportunity Venture (Asia), and showed five working prototypes at MWC 2026 and again at VivaTech in June 2026. It aims to finish a full prototype by the end of 2026 and has told the press that a version could reach shelves as soon as 2030. The conclusion is that eye-worn displays remain a development programme, and the first consumer products depend on safety testing that has not yet been published.
The brief treats smart contact lenses as an emerging signal with a ten year horizon to 2036. It identifies which eye care companies, device makers and technology groups capture value as lenses move from prototypes to regulated products. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.
| Parameter | Details |
|---|---|
| Forward horizon | 2026–2036 (10 years) |
| Emerging force | Smart contact lenses |
| Technology readiness | One FDA-approved monitoring lens on the market; glucose, drug-delivery and display lenses at prototype and preclinical stage |
| Indicative market size & forecast | The smart contact lenses market, covering electronic and sensing contact lenses for intraocular pressure monitoring, glucose sensing, drug delivery and eye-worn displays, including regulated monitoring lenses and clinical and development programme revenue, and excluding non-electronic vision-correction and myopia-control lenses and smart glasses, is valued at USD 0.02–0.05 billion in 2026 and is projected to reach USD 1.15–2.88 billion by 2036, at a CAGR of 50% |
| Mainstream inflection | ~2031, when a lens for glucose or pressure monitoring with a clinical claim and a display lens for consumers are both available through regulated channels |
| Signal strength | An approved monitoring lens, a USD 250 million round for a display lens developer and a published drug-releasing lens in animals |
| Primary beneficiaries | Eye care and contact lens companies; medical device makers; technology groups; patients with glaucoma and diabetes |
| Brief length / format | 104 pages · PDF + executive summary deck · instant delivery |
Understanding the Technology
Sensing lenses measure the eye and its fluids. Pressure lenses track changes in the shape of the cornea, and glucose lenses read tear glucose with an electrode. Published studies often have small samples and wear times under 72 hours, and tear glucose is harder to relate to blood glucose than to the fluid in tissue. The conclusion is that clinical proof of accuracy is the main step between a prototype and a medical claim.
Drug-delivery lenses release a medicine at the right time. The Terasaki lens uses a soft chamber that changes volume when pressure changes the cornea and releases drug without a battery, and other lenses release drugs on chemical triggers. The conclusion is that treatment lenses face the stricter drug-device approval route, which takes longer than monitoring.
Display lenses place pixels on the eye. XPANCEO describes a micro display built into the lens, with wireless power from a case, and notes that radiation is comparable to Bluetooth headphones, which outside testing has not yet confirmed. Another company in the field has a micro LED display about 0.48 mm across. The conclusion is that power, heat and safety, not the display itself, set the timeline for consumer lenses.
Power and data are the engineering limits. A lens has no room for a battery of useful size, so power comes from wireless charging or from designs without electronics, and data pass to a phone. The conclusion is that designs without batteries suit medical monitoring first, and displays depend on wireless power developments.
The limits are clinical proof of accuracy, safe wear time and comfort, regulatory approval, cost and the lack of insurance coverage for new devices. The brief tests each limit against the evidence to 2036.
Market Outlook
The smart contact lenses market, covering electronic and sensing contact lenses for intraocular pressure monitoring, glucose sensing, drug delivery and eye-worn displays, including regulated monitoring lenses and clinical and development programme revenue, and excluding non-electronic vision-correction and myopia-control lenses and smart glasses, is valued at USD 0.02–0.05 billion in 2026 and is projected to reach USD 1.15–2.88 billion by 2036, at a CAGR of 50%.
The 2026 base rests on sales of the one regulated monitoring lens, clinical and development programme revenue, and early sales to research users. Growth then follows regulatory approvals, the number of lens wearers with a clinical indication, the price per lens and the launch of display lenses.
The forecast is sensitive to the results of the first human trials, the speed of approval for monitoring and treatment lenses and the safety record of display lenses.
Scenarios
Scenarios.
The base case assumes that a pressure or glucose lens enters pivotal trials by 2029, that a second regulated monitoring lens is approved by 2031 and that a display lens reaches limited consumer sale by 2032, bringing the inflection to about 2031 and a 2036 value near the middle of the range. An accelerated case assumes that human trials confirm accuracy early and that display lenses launch by 2030, moving the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes that trials show poor accuracy and that safety questions delay displays, moving the inflection to 2034 and holding growth at the bottom of the range.
Factors Behind Growth
Growth drivers
- Large unmet need for continuous monitoring in glaucoma and diabetes.
- Venture funding for display lens developers.
- Published prototypes of lenses that sense and release drugs.
- One FDA-approved monitoring lens as a regulatory precedent.
Enablers
- Soft flexible electronics and polymers.
- Micro displays and wireless power.
- Tear fluid and pressure sensors.
- Phone connectivity and artificial intelligence for readings.
Restraints and barriers
- Lack of human data on accuracy.
- Limits on wear time, comfort and safety.
- Longer approval route for drug-delivery lenses.
- Cost and lack of insurance coverage.
The Forces at Play
The direction of smart contact lenses is set by clinical evidence, regulatory approval, the safety of power and display designs and the willingness of eye care companies and technology groups to invest.
The brief assesses standards and policy, company and investor funding, technology readiness, product and manufacturing readiness and customer readiness, and rates each force for direction, speed and confidence.
Adoption Outlook
How the shift is likely to unfold across three time horizons.
Monitoring lenses enter human trials, display prototypes are finished and the first partnerships with eye care companies are signed.
A second monitoring lens is approved, and the first display lenses reach consumers in limited markets.
Lenses combine monitoring, treatment and display with phone and clinical systems.
Latest Strategic Developments
| Date | Development | Type | Significance |
|---|---|---|---|
| Jul 2025 | XPANCEO raises USD 250 million at a USD 1.35 billion valuation, led by Opportunity Venture (Asia) | Funding | Funds display lens development |
| Mar 2026 | XPANCEO shows five working smart lens prototypes at MWC 2026 | Product | Shows display and sensing prototypes |
| Apr 2026 | The Terasaki Institute reports a drug-releasing pressure-sensing lens in Science Translational Medicine | Research | Shows a lens that senses and treats in animals |
| Jun 2026 | XPANCEO shows its prototypes again at VivaTech and targets a full prototype by the end of 2026 | Product | Sets a prototype date |
| 2026 | Researchers report a lens with a resistive pressure sensor for real-time monitoring in npj Flexible Electronics | Research | Adds a new sensing design |
| Late 2026 | XPANCEO plans to complete its first full prototype and show it in early 2027 | Programme | Marks the first full display lens |
Key Players & Competitive Landscape
The key participants in smart contact lenses include Alcon Inc., Johnson & Johnson, The Cooper Companies, Inc., Bausch + Lomb Corporation, Menicon Co., Ltd., EssilorLuxottica SA, Hoya Corporation, Glaukos Corporation, Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Carl Zeiss Meditec AG, Abbott Laboratories, Dexcom, Inc., Medtronic plc, Samsung Electronics Co., Ltd., Sony Group Corporation, Apple Inc., Meta Platforms, Inc., Konica Minolta, Inc., Alphabet Inc., Sensimed, XPANCEO, Mojo Vision, the Terasaki Institute for Biomedical Innovation and Intra-Ker.
The brief profiles representative participants in each archetype and assesses which are positioned to lead as lenses move from prototypes to regulated products.
Alcon Inc., Johnson & Johnson and The Cooper Companies, Inc. lead among contact lens companies, Sensimed leads among regulated monitoring lenses and XPANCEO leads among display lens developers by funding. Competitive intensity is low and rising as large eye care groups and technology groups enter.
| Archetype | Representative players | Position | Outlook |
|---|---|---|---|
| Contact lens and eye care companies | Alcon Inc., Johnson & Johnson, The Cooper Companies, Inc., Bausch + Lomb Corporation, Menicon Co., Ltd., EssilorLuxottica SA, Hoya Corporation | Contact lenses and eye care | Offer distribution, manufacturing and clinical access |
| Glaucoma and ocular drug companies | Glaukos Corporation, Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Carl Zeiss Meditec AG | Eye disease treatment and diagnostics | Provide drugs and clinical partnerships |
| Diabetes monitoring companies | Abbott Laboratories, Dexcom, Inc., Medtronic plc | Glucose monitoring | Offer glucose sensing expertise and reimbursement experience |
| Technology groups | Samsung Electronics Co., Ltd., Sony Group Corporation, Apple Inc., Meta Platforms, Inc., Alphabet Inc., Konica Minolta, Inc. | Displays, sensors and wearables | Supply displays, sensors and wearable platforms |
| Lens developers | Sensimed, XPANCEO, Mojo Vision | Smart lenses | Develop monitoring and display lenses |
| Research bodies | Terasaki Institute for Biomedical Innovation, Intra-Ker | Research and devices | Develop new sensing and drug-delivery designs |
Where value migrates.
In 2026 value sits with developers that hold the approved monitoring lens and the funded display prototypes. By 2031 it moves toward eye care companies that supply manufacturing and clinical access, and toward diabetes and glaucoma companies that hold reimbursement and care pathways. By 2036 it settles with companies that combine lens manufacturing, sensing and data services, and with technology groups that run display platforms. Margins hold for regulated monitoring products and narrow for lenses sold on display features alone.
Who Will Win — and Why
The archetypes best positioned to capture value as the shift matures.
Lens makers have the production and clinical channels that start-ups lack.
An approved lens shows the path to clinical use and reimbursement.
Displays and power are the main limits for consumer lenses.
Regulatory Landscape
| Jurisdiction | Milestone | Indicative timing | Effect on adoption |
|---|---|---|---|
| FDA device approval | Triggerfish is FDA approved for 24-hour pressure-related monitoring in glaucoma | Approved | Sets the precedent for monitoring lenses |
| Drug-device combination rules | Lenses that release drugs face stricter standards than monitoring lenses | Ongoing | Lengthens the path for treatment lenses |
| Consumer product safety | Display lenses must show eye safety for continuous wear, including heat and radiation | Emerging | Sets the timeline for display lenses |
| Clinical evidence standards | Trials larger than current small studies with wear times under 72 hours are needed | Ongoing | Defines the evidence required |
| Reimbursement | Payers decide coverage for monitoring lenses | Emerging | Decides the size of clinical sales |
Investment Signals
Unmet clinical need, venture funding, published prototypes and an approved precedent support growth, while the lack of human data, wear and safety limits, the longer route for drug-delivery lenses and cost hold back the pace.
A trial result, a regulatory decision or a safety finding could shift the pace. The brief therefore tracks four indicators: human trials started, regulatory approvals, funding and partnerships with eye care companies, and wear time achieved.
Human trials, then a second regulated monitoring lens, then display lenses and combined platforms is the expected order of change.
Questions This Brief Answers
Strategic Implications
- Eye care companies: partner with lens developers for manufacturing and clinical access, starting with monitoring.
- Glaucoma and diabetes companies: test lenses against standard monitoring and plan reimbursement.
- Lens developers: publish human accuracy and safety data and prepare for regulatory filings.
- Technology groups: develop wireless power and displays that meet eye safety needs.
- Investors: favour developers with regulatory progress and clinical partners over those with display prototypes only.
"The first lenses that matter will measure the eye. The ones that follow will put the screen in it."
Table of Contents
Access & Licensing
A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.
every brief